These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 7558420

  • 1. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
    Mellish KJ, Barnard CF, Murrer BA, Kelland LR.
    Int J Cancer; 1995 Sep 15; 62(6):717-23. PubMed ID: 7558420
    [Abstract] [Full Text] [Related]

  • 2. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF, Hunakova L, Kelland LR.
    Chem Biol Interact; 1999 Nov 15; 123(1):11-29. PubMed ID: 10597899
    [Abstract] [Full Text] [Related]

  • 3. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
    Mellish KJ, Barnard CF, Kelland LR, Harrap KR.
    Int J Cancer; 1994 Oct 01; 59(1):65-70. PubMed ID: 7927906
    [Abstract] [Full Text] [Related]

  • 4. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
    Kelland LR, Barnard CF, Mellish KJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA, Harrap KR.
    Cancer Res; 1994 Nov 01; 54(21):5618-22. PubMed ID: 7923207
    [Abstract] [Full Text] [Related]

  • 5. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
    O'Neill CF, Ormerod MG, Robertson D, Titley JC, Cumber-Walsweer Y, Kelland LR.
    Br J Cancer; 1996 Oct 01; 74(7):1037-45. PubMed ID: 8855971
    [Abstract] [Full Text] [Related]

  • 6. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM, Orr RM, Valenti MR, Barnard CF, Murrer BA, Kelland LR, Harrap KR.
    Anticancer Res; 1996 Oct 01; 16(1):33-8. PubMed ID: 8615631
    [Abstract] [Full Text] [Related]

  • 7. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, Harrap KR.
    Cancer Res; 1992 Jul 15; 52(14):3857-64. PubMed ID: 1617660
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ, Kelland LR.
    Cancer Res; 1994 Dec 01; 54(23):6194-200. PubMed ID: 7954466
    [Abstract] [Full Text] [Related]

  • 9. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY, Rogers PM, Kelland LR.
    Clin Cancer Res; 1995 Sep 01; 1(9):981-9. PubMed ID: 9816070
    [Abstract] [Full Text] [Related]

  • 10. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
    Raynaud FI, Odell DE, Kelland LR.
    Br J Cancer; 1996 Aug 01; 74(3):380-6. PubMed ID: 8695352
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ, Kelland LR, Harrap KR.
    Br J Cancer; 1993 Aug 01; 68(2):240-50. PubMed ID: 8347478
    [Abstract] [Full Text] [Related]

  • 14. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.
    Cancer Res; 1993 Jun 01; 53(11):2581-6. PubMed ID: 8388318
    [Abstract] [Full Text] [Related]

  • 15. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF, Koberle B, Masters JR, Kelland LR.
    Br J Cancer; 1999 Dec 01; 81(8):1294-303. PubMed ID: 10604725
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines.
    Kido Y, Khokhar AR, Siddik ZH.
    Anticancer Drugs; 1993 Apr 01; 4(2):251-8. PubMed ID: 8490203
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W, Chaney SG.
    Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361
    [Abstract] [Full Text] [Related]

  • 20. Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells.
    Farrell N, Povirk LF, Dange Y, DeMasters G, Gupta MS, Kohlhagen G, Khan QA, Pommier Y, Gewirtz DA.
    Biochem Pharmacol; 2004 Sep 01; 68(5):857-66. PubMed ID: 15294448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.